Lecanemab: What Patients Need to Know

Lecanemab is a medicine used for some people with early Alzheimer's disease. It does not cure Alzheimer's, but it may slow cognitive decline in carefully selected patients who have confirmed amyloid buildup in the brain.

What lecanemab is and who it is for

Lecanemab is a prescription medicine used in certain people with early Alzheimer’s disease. In simple terms, it is an antibody treatment that targets amyloid, a protein that can build up in the brain in Alzheimer’s disease. The goal is not to cure dementia, but to slow the worsening of memory and thinking problems in patients who meet specific criteria.

This treatment is generally considered for people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia, after tests confirm amyloid in the brain. It is not meant for every person with memory loss, because memory symptoms can have many causes. Careful diagnosis is an essential first step.

Lecanemab is given by intravenous infusion on a regular schedule in a supervised medical setting. Because the medicine can have important side effects, doctors usually combine treatment with MRI monitoring, routine follow-up, and a review of other health conditions and medications.

How lecanemab works

Lecanemab belongs to a group of medicines sometimes called anti-amyloid monoclonal antibodies. These treatments are designed to bind to forms of amyloid-beta and help clear them from the brain. Amyloid is one of the hallmark proteins associated with Alzheimer’s disease, although it is not the only change involved in the illness.

By reducing amyloid burden, lecanemab may help slow the rate of decline in thinking and daily function for some patients. This is an important point for patients and families: slowing decline is different from restoring lost memory or bringing the brain back to normal. Expectations should be realistic and discussed openly before treatment begins.

Because Alzheimer’s disease is complex, amyloid treatment is only one part of care. Patients may still need support for sleep, mood, nutrition, daily routine, physical activity, and safety at home. A broader care plan often remains just as important as the medicine itself.

Who may be eligible for treatment

Eligibility for lecanemab usually starts with the stage of disease. It is intended for people in the early symptomatic phase of Alzheimer’s disease, rather than those with moderate or advanced dementia. Doctors generally look for mild but noticeable changes in memory or thinking that fit an Alzheimer’s pattern.

Another key requirement is confirmation of amyloid pathology. This may be done with amyloid PET imaging or laboratory testing of cerebrospinal fluid, depending on the clinical setting. Without evidence of amyloid, lecanemab is not considered appropriate because the treatment specifically targets that protein.

Doctors also assess other factors that may affect safety. These can include MRI findings, a history of stroke or brain bleeding, use of blood thinners, and overall medical stability. In some cases, genetic testing for APOE status may be discussed because it can help estimate the risk of certain side effects, although testing decisions are individualized.

Many patients being evaluated for memory symptoms first undergo a broader work-up for Alzheimer's disease and other causes of cognitive change. If infusion therapy is being considered, the care team may also explain how neurology care helps coordinate diagnosis, imaging, treatment planning, and follow-up.

Potential benefits and what results to expect

The main potential benefit of lecanemab is a slower rate of decline in cognition and daily functioning compared with no anti-amyloid treatment. For some patients and families, even a modest slowing can be meaningful because it may help preserve independence for longer. However, the amount of benefit varies, and not every patient will experience the same result.

Lecanemab does not cure Alzheimer’s disease. It also does not stop the disease completely, and it does not typically improve memory in a dramatic or immediate way. Patients should think of it as one option within a long-term treatment strategy rather than a standalone answer.

Doctors usually discuss benefits in practical terms, such as whether the treatment may help slow changes in memory, conversation, planning, or everyday tasks over time. Shared decision-making is important, especially because treatment requires repeat infusions, repeat MRI scans, and regular clinic visits.

Risks, side effects, and monitoring

The most important safety issue with lecanemab is a treatment-related brain imaging change called ARIA, short for amyloid-related imaging abnormalities. ARIA can involve swelling in the brain or small areas of bleeding seen on MRI. Some people have no symptoms, while others may develop headache, confusion, dizziness, nausea, vision changes, or worsening neurologic symptoms.

Because of this risk, doctors usually order MRI scans before treatment and at scheduled points during therapy. Monitoring may be more cautious in patients with higher-risk MRI findings or in those taking medicines that increase bleeding risk. If ARIA is detected, treatment may need to be paused, adjusted, or stopped depending on severity and symptoms.

Infusion-related reactions can also occur. These may include feverish feelings, chills, rash, changes in blood pressure, or discomfort during or after the infusion. The treatment team observes patients during infusions and provides guidance on what symptoms to report after going home.

In rare situations, severe complications may occur, which is why patient selection matters. People with stroke symptoms, sudden severe headache, new confusion, or seizures during treatment need urgent medical evaluation. If specialists suspect another neurological issue, a broader assessment that may include brain check-up services can help clarify the cause.

How diagnosis and treatment planning are done

Before recommending lecanemab, doctors usually confirm that memory symptoms are due to Alzheimer’s disease rather than another condition. The evaluation often includes a medical history, cognitive testing, blood work, brain MRI, and sometimes more specialized tests. Depending on the case, this may also include tests to look for depression, thyroid disease, vitamin deficiencies, sleep disorders, or vascular causes of cognitive decline.

Amyloid confirmation is a central part of treatment planning. This can be done through amyloid PET scans or cerebrospinal fluid analysis when available and appropriate. MRI is also used to look for signs that could raise the risk of treatment-related bleeding or swelling.

Planning usually involves a detailed conversation with the patient and family. Doctors explain what the treatment can and cannot do, how often infusions are needed, what follow-up imaging is expected, and what warning symptoms should prompt a call or urgent assessment. In some settings, advanced imaging such as MRI plays an important role in both screening and ongoing monitoring.

Living with treatment: practical self-care and support

People receiving lecanemab often do best when medication is combined with comprehensive memory care. This may include a structured daily routine, regular physical activity, attention to hearing and vision, good sleep habits, and support for mood and stress. These steps do not replace treatment, but they can help maintain function and quality of life.

Families and caregivers play a central role. Keeping a record of symptoms, appointments, infusion dates, and MRI schedules can make treatment easier to manage. It can also help the care team notice whether symptoms are stable, gradually changing, or affected by another health issue.

Medication review is especially important. Patients should tell their doctor about blood thinners, antiplatelet medicines, supplements, and any history of stroke or brain hemorrhage. They should not start or stop medicines on their own, but they should ask whether each medication is safe to continue during treatment.

For international patients seeking coordinated assessment, Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat neurological conditions with individualized planning and follow-up.

When to seek medical care

Medical advice should be sought promptly if memory loss, confusion, language problems, or changes in judgment are affecting daily life. These symptoms are not always caused by Alzheimer’s disease, so an evaluation is important even when changes seem mild. Early assessment may open the door to more treatment options and better long-term planning.

People already receiving lecanemab should contact their doctor right away if they develop new headache, confusion, dizziness, vision changes, trouble walking, weakness, numbness, or seizure-like activity. These symptoms do not always mean a serious complication, but they need timely assessment because they can be linked to ARIA or another neurological problem.

Emergency care is needed for sudden stroke-like symptoms, loss of consciousness, severe worsening confusion, or a sudden severe headache. Patients and caregivers should receive clear instructions from the treatment team about whom to call and when to go directly to urgent or emergency care.

Frequently asked questions

Is lecanemab a cure for Alzheimer's disease?

No. Lecanemab is not a cure, and it does not reverse Alzheimer's disease. Its role is to slow decline in some people with early Alzheimer's who have confirmed amyloid pathology.

Who can receive lecanemab?

It is generally considered for people with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia. A doctor must confirm amyloid buildup and review MRI findings, medical history, and overall safety before treatment starts.

How is lecanemab given?

Lecanemab is given by intravenous infusion in a clinical setting. Patients also need follow-up appointments and scheduled MRI scans to monitor for treatment-related brain changes.

What are the main side effects of lecanemab?

The main concern is ARIA, which refers to brain swelling or small areas of bleeding seen on MRI. Some people have no symptoms, while others may develop headache, confusion, dizziness, nausea, or visual changes.

Why are MRI scans needed during treatment?

MRI scans help doctors detect ARIA early, even when a patient feels well. This allows the care team to decide whether treatment can continue safely or whether it should be paused or adjusted.

Can a person on blood thinners take lecanemab?

This depends on the individual situation and should be reviewed carefully by the treating doctor. Blood thinners and certain MRI findings may increase bleeding risk, so treatment decisions need a personalized safety assessment.

What should patients and families expect from treatment?

The aim is usually a slower rate of decline rather than noticeable improvement in memory. Families should expect regular infusions, monitoring, and ongoing support for daily function, safety, and caregiver needs.

References

• U.S. Food and Drug Administration
• National Institute on Aging
• Alzheimer's Association
• American Academy of Neurology
• Centers for Disease Control and Prevention

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.